^
Association details:
| Biomarker: | TP53 mutation + Chr del(17p) |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Yinuokai (orelabrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
131 | Updated Efficacy and Safety Results of Orelabrutinib in the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia
Published date:
06/09/2021
Excerpt:
This is an open-label, multicenter, phase II study to evaluate the safety and efficacy following an oral daily administration of orelabrutinib....A total of 80 patients with r/r CLL/SLL were enrolled....The ORR was 100% in patients with Del(17p) and/or TP53 mutation....The ORR was 94.7% for Del(11q)) and 93.9% for unmutated IGHV....Orelabrutinib provides a favorable therapeutic choice for patients with r/r CLL/SLL.
Source:
Title:
Updated Results from the Phase II Study of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia
Published date:
11/04/2020
Excerpt:
Following a minimum of 12 cycles treatment, the ORR (PR-L or above) was 91.3% (95% confidence interval [CI]: 82.80ļ½96.41%) with 10.0% of patients having complete response (CR), 63.8% PR and 17.5% PR-Lā¦.Patients with Del(17p) and/or TP53 mutation achieved 100% ORR. The ORR is 94.7% for Del(11q)) and 93.9% for unmutated IGHV.
